Verrica Pharmaceuticals (VRCA) Assets Average (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Assets Average of $43.0 million for Q1 2026, down 10.79% year-over-year from $48.2 million in Q1 2025, and down 2.4% quarter-over-quarter from $44.0 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Assets Average (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $43.0 million for Q1 2026.
- In Q1 2026, Assets Average fell 10.79% year-over-year to $43.0 million; the TTM figure through Mar 2026 stood at $43.0 million (down 10.79% YoY), while the FY2025 annual figure was $50.6 million, down 25.39% from the prior year.
- Assets Average for Q1 2026 stood at $43.0 million, down from $44.0 million in the prior quarter.
- The five-year high for Assets Average was $89.4 million in Q4 2023, with the low at $40.0 million in Q3 2025.
- The 5-year median for Assets Average is $56.3 million (2022), against an average of $57.2 million.
- The sharpest annual moves came in 2023 and 2024: Assets Average jumped 90.42% in 2023, then plunged 51.29% in 2024.
- Verrica Pharmaceuticals' Assets Average stood at $46.9 million in 2022, then surged by 90.42% to $89.4 million in 2023, then slumped by 51.29% to $43.5 million in 2024, then climbed by 1.11% to $44.0 million in 2025, then dropped by 2.4% to $43.0 million in 2026.
- Business Quant data shows VRCA's Assets Average at $43.0 million in Q1 2026, $44.0 million in Q4 2025, and $40.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Verrica Pharmaceuticals | 99.71 Mn | 88.51 Mn | - | 37.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.40 Mn |
| Mar 31, 2026 | 42.96 Mn |
| Dec 31, 2025 | 44.01 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.64 Mn |
| Mar 31, 2025 | 48.16 Mn |
| Dec 31, 2024 | 43.53 Mn |
| Sep 30, 2024 | 42.47 Mn |
| Jun 30, 2024 | 59.16 Mn |
| Mar 31, 2024 | 73.95 Mn |
| Dec 31, 2023 | 89.37 Mn |
| Sep 30, 2023 | 79.67 Mn |
| Jun 30, 2023 | 65.42 Mn |
| Mar 31, 2023 | 56.68 Mn |
| Dec 31, 2022 | 46.93 Mn |
| Sep 30, 2022 | 56.29 Mn |
| Jun 30, 2022 | 67.53 Mn |
| Mar 31, 2022 | 75.87 Mn |
| Dec 31, 2021 | 84.44 Mn |
| Sep 30, 2021 | 93.89 Mn |